Annual EBITDA:
-$51.38M-$17.58M(-52.00%)Summary
- As of today, TRVI annual EBITDA is -$51.38 million, with the most recent change of -$17.58 million (-52.00%) on December 31, 2024.
- During the last 3 years, TRVI annual EBITDA has fallen by -$18.95 million (-58.44%).
- TRVI annual EBITDA is now -524.04% below its all-time high of -$8.23 million, reached on December 31, 2017.
Performance
TRVI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$13.68M-$2.25M(-19.69%)Summary
- As of today, TRVI quarterly EBITDA is -$13.68 million, with the most recent change of -$2.25 million (-19.69%) on June 30, 2025.
- Over the past year, TRVI quarterly EBITDA has dropped by -$433.00 thousand (-3.27%).
- TRVI quarterly EBITDA is now -516.12% below its all-time high of -$2.22 million, reached on December 1, 2017.
Performance
TRVI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$51.37M-$433.00K(-0.85%)Summary
- As of today, TRVI TTM EBITDA is -$51.37 million, with the most recent change of -$433.00 thousand (-0.85%) on June 30, 2025.
- Over the past year, TRVI TTM EBITDA has dropped by -$8.34 million (-19.39%).
- TRVI TTM EBITDA is now -2213.06% below its all-time high of -$2.22 million, reached on December 1, 2017.
Performance
TRVI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TRVI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -52.0% | -3.3% | -19.4% |
| 3Y3 Years | -58.4% | -75.2% | -71.1% |
| 5Y5 Years | -93.1% | -84.9% | -71.1% |
TRVI EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -71.8% | at low | -106.0% | +2.6% | -72.0% | +0.0% |
| 5Y | 5-Year | -93.1% | at low | -106.0% | +2.6% | -72.0% | +0.0% |
| All-Time | All-Time | -524.0% | at low | -516.1% | +2.6% | -2213.1% | +0.0% |
TRVI EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$13.68M(-19.7%) | -$51.37M(-0.9%) |
| Mar 2025 | - | -$11.43M(+6.3%) | -$50.94M(+0.9%) |
| Dec 2024 | -$51.38M(-52.0%) | -$12.21M(+13.1%) | -$51.38M(-6.9%) |
| Sep 2024 | - | -$14.05M(-6.0%) | -$48.07M(-11.7%) |
| Jun 2024 | - | -$13.25M(-11.6%) | -$43.03M(-12.9%) |
| Mar 2024 | - | -$11.87M(-33.4%) | -$38.13M(-12.8%) |
| Dec 2023 | -$33.80M(-13.0%) | -$8.90M(+1.2%) | -$33.80M(-7.2%) |
| Sep 2023 | - | -$9.01M(-7.9%) | -$31.54M(-2.0%) |
| Jun 2023 | - | -$8.35M(-10.7%) | -$30.93M(-1.8%) |
| Mar 2023 | - | -$7.54M(-13.6%) | -$30.39M(-1.8%) |
| Dec 2022 | -$29.90M(+7.8%) | -$6.64M(+20.9%) | -$29.86M(+5.1%) |
| Sep 2022 | - | -$8.40M(-7.5%) | -$31.48M(-4.9%) |
| Jun 2022 | - | -$7.81M(-11.4%) | -$30.02M(+4.3%) |
| Mar 2022 | - | -$7.01M(+15.1%) | -$31.36M(+3.3%) |
| Dec 2021 | -$32.43M | -$8.26M(-19.1%) | -$32.43M(+2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$6.93M(+24.3%) | -$33.34M(+0.9%) |
| Jun 2021 | - | -$9.15M(-13.4%) | -$33.64M(-5.5%) |
| Mar 2021 | - | -$8.08M(+12.0%) | -$31.89M(+1.7%) |
| Dec 2020 | -$32.44M(-21.9%) | -$9.18M(-27.0%) | -$32.44M(-8.1%) |
| Sep 2020 | - | -$7.23M(+2.3%) | -$30.02M(+1.3%) |
| Jun 2020 | - | -$7.40M(+14.2%) | -$30.43M(+0.0%) |
| Mar 2020 | - | -$8.63M(-27.7%) | -$30.43M(-14.4%) |
| Dec 2019 | -$26.61M(-44.7%) | -$6.76M(+11.5%) | -$26.61M(-3.3%) |
| Sep 2019 | - | -$7.64M(-3.1%) | -$25.77M(-42.1%) |
| Jun 2019 | - | -$7.41M(-54.2%) | -$18.13M(-20.1%) |
| Mar 2019 | - | -$4.80M(+18.8%) | -$15.10M(-46.7%) |
| Dec 2018 | -$18.39M(-123.3%) | -$5.92M(-35.2%) | -$10.29M(-56.0%) |
| Jun 2018 | - | -$4.38M(-97.0%) | -$6.60M(-197.0%) |
| Dec 2017 | -$8.23M(+4.5%) | - | - |
| Dec 2017 | - | -$2.22M | -$2.22M |
| Dec 2016 | -$8.62M | - | - |
FAQ
- What is Trevi Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Trevi Therapeutics, Inc.?
- What is Trevi Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Trevi Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Trevi Therapeutics, Inc.?
- What is Trevi Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Trevi Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Trevi Therapeutics, Inc.?
- What is Trevi Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Trevi Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of TRVI is -$51.38M
What is the all-time high annual EBITDA for Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. all-time high annual EBITDA is -$8.23M
What is Trevi Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, TRVI annual EBITDA has changed by -$17.58M (-52.00%)
What is Trevi Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of TRVI is -$13.68M
What is the all-time high quarterly EBITDA for Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. all-time high quarterly EBITDA is -$2.22M
What is Trevi Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, TRVI quarterly EBITDA has changed by -$433.00K (-3.27%)
What is Trevi Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of TRVI is -$51.37M
What is the all-time high TTM EBITDA for Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. all-time high TTM EBITDA is -$2.22M
What is Trevi Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, TRVI TTM EBITDA has changed by -$8.34M (-19.39%)